Peter Kabos
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (19)
Progesterone receptors (PRs) can regulate transcription by RNA polymerase III (Pol III), which transcribes small non-coding RNAs, including all transfer RNAs (tRNAs). We previously demonstrated that PR is associated with the Pol III complex at tRNA genes and that progestins downregulate tRNA transcripts in breast tumor models. To define this mechanism, we investigated the interplay between PR, the Pol III repressor Maf1, and TFIIIB, a core transcription component. ChIP-seq was performed for PR, the Pol III subunits POLR3A, POLR3C, and POLR3G, the TFIIIB component Brf1, and Maf1 in breast cancer cells with or without progestin treatment. With progestin treatment, PR localized to ∼50% of POLR3A-occupied tRNA genes, with Maf1 co-recruited at many of these sites. Progestin treatment did not significantly alter the number of tRNA genes occupied by Pol III subunits or Brf1; however, Brf1 occupancy was stabilized. Progestins downregulated nascent transcription of one-third of tRNA genes; this repression was attenuated by Maf1 knockdown, indicating that Maf1 is required. The PR and Maf1 interaction was also detected by co-immunoprecipitation in a progestin-dependent manner. Overall, these findings demonstrate a ligand-dependent PR-mediated repression of tRNA transcription that involves Maf1.
Year:
2025
Purpose: This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor–positive, HER2− advanced breast cancer. Patients and Methods: SERENA-1 (NCT03616587) is a phase I, multipart, open-label study in women with refractory estrogen receptor–positive, HER2− advanced breast cancer. Patients received oral once-daily camizestrant 75 or 150 mg plus abemaciclib; camizestrant 75, 150, or 300 mg plus palbociclib; or camizestrant 75 mg plus ribociclib 400 or 600 mg. Safety/tolerability, pharmacokinetics, efficacy, and impact on estrogen receptor 1 mutation ctDNA were assessed. Results: By September 16, 2024 (data cutoff), 53 patients had received camizestrant plus abemaciclib, 78 camizestrant plus palbociclib, and 60 camizestrant plus ribociclib. Patients had a median of 2 (range, 0–7) prior regimens for advanced disease; 83% had received a prior CDK4/6i and 59% prior fulvestrant. The most common treatment-emergent adverse events for camizestrant 75 mg (phase III dose) plus each CDK4/6i were diarrhea [with abemaciclib (87.5%)] and neutropenia [with palbociclib (80%) and ribociclib (32.1% for 400 mg and 53.1% for 600 mg)]. The median camizestrant t max was ∼4 hours postdose across combinations, with an estimated half-life of 9.5 to 17 hours. No clinically meaningful drug–drug interactions were evident. In this heavily pretreated population, CBR 24 was 49.5% and the median progression-free survival was 7.4 months (95% confidence interval, 5.3–9.3), with antitumor activity across all combinations, including patients previously treated with CDK4/6i and/or fulvestrant, with or without estrogen receptor 1 mutation. Conclusions: Camizestrant is well tolerated, with antitumor activity in combination with CDK4/6i. These results support the evaluation of camizestrant 75 mg plus standard CDK4/6i doses in phase III trials.
Year:
2025
ESR1 m ctDNA dynamics for each CDK4/6i + camizestrant combination. (Top) waterfall plot showing percentage change in ESR1 m summed VAF at C2D1 compared with C1D1 in each evaluable patient. (Middle) vector plot showing absolute ESR1 m ctDNA change. The dots indicate the summed VAF observed in the C1D1 sample (magenta) and the C2D1 sample (black). (Bottom) tile plot of ESR1 m identified in each patient by ctDNA. ESR1 m was defined as a mutation that gives rise to one of the following amino acid changes: E380Q, V422del, S463P, L536H/P/R, Y537C/D/N/S, or D538G. C1D1, cycle 1, day 1; C2D1, cycle 2, day 1; nd, not detected; sVAF, summed variant allele frequency; VAF, variant allele frequency.
Year:
2025
AE profile for camizestrant in combination with abemaciclib, palbociclib, or ribociclib (irrespective of causality); AEs reported in ≥20% of patients. a
Year:
2025
AEs leading to dose reduction or discontinuation in patients treated with camizestrant 75, 150, or 300 mg combined with either abemaciclib, palbociclib, or ribociclib. Description data are presented as number and % of patients. N, number; NA, not applicable.
Year:
2025
ORR, CBR 24 , and median PFS for ( A ) camizestrant in combination with abemaciclib, palbociclib, or ribociclib; ( B ) subgroup analysis pooled across all camizestrant + CDK4/6i combinations. NC is represented by an arrowed line in the plots and is not representative of the data. N, no; NC, not calculated; Y, yes. Data in % represent 95% CI.
Year:
2025
Best overall response and target lesion improvement. Percentage change from baseline in the sum of the diameters of all target lesions at the time of best response. There were five subjects with 100% target lesion responses, but they were classified as PR due to nontarget lesions. Each bar represents a single patient with no prior systemic therapy for advanced breast cancer in the response evaluable set ( N = 33).
Year:
2025
Purpose: Nonclinical evidence demonstrating that estrogen receptor, cyclin-dependent kinases 4 and 6 (CDK4/6), and PI3K/AKT/mTOR (PAM) pathways cross-promote tumor proliferation in hormone receptor–positive (HR+)/HER2− breast cancer cell lines led to the development of CDK4/6 inhibitors and agents inhibiting single PAM pathway nodes to treat HR+/HER2− advanced breast cancer. Simultaneous blockade of the estrogen receptor, CDK4/6, and PAM pathways may optimize antitumor control in the treatment-naïve advanced breast cancer setting. Gedatolisib, a pan-PI3K/mTOR inhibitor, was evaluated as first-line therapy, combined with standard-of-care palbociclib and letrozole, for patients with HR+/HER2− advanced breast cancer. Patients and Methods: Treatment-naïve patients from a phase Ib study with HR+/HER2− advanced breast cancer treated with gedatolisib plus palbociclib and letrozole were analyzed. The primary endpoint of the overall study was investigator-assessed objective response. Secondary endpoints included safety, duration of response, progression-free survival (PFS), and overall survival. Results: Of 41 patients, all had stage IV disease, 93% had measurable disease, 78% had visceral metastases, and 22% had detectable PIK3CA mutations. The objective response rate was 79% in patients with evaluable disease ( N = 33). The median duration of response was 48 months for confirmed responders. The median PFS was 48.4 months, and the median overall survival was 77.3 months. The overall response rate and PFS were comparable in patients with and without PIK3CA mutations. Fewer than 10% discontinued treatment due to treatment-related adverse events. The most frequent grade 3/4 adverse events were neutropenia (61%), rash (39%), and oral stomatitis (29%). Conclusions: Gedatolisib plus palbociclib and letrozole demonstrated preliminary efficacy in patients with no prior systemic therapy for advanced breast cancer. These results warrant further evaluation of gedatolisib added to standard-of-care, first-line therapy for HR+/HER2− advanced breast cancer.
Year:
2025
Survival in patients with no prior systemic therapy for advanced breast cancer in the full analysis population. Kaplan–Meier curve determined in the full analysis population of ( A ) PFS and ( B ) OS. PFS was determined by the time from the date of the first dose of study drug to the date of the first radiologic documentation of postbaseline disease progression or death due to any cause. OS was defined as the time from the start of the study drug to death due to any cause.
Year:
2025
Purpose: To overcome resistance to antihormonal and HER2-targeted agents mediated by cyclin D1-CDK4/6 complex, we proposed an oral combination of the HER2 inhibitor tucatinib, aromatase inhibitor letrozole, and CDK4/6 inhibitor palbociclib (TLP combination) for treatment of HR+/HER2+ metastatic breast cancer (MBC). Patients and Methods: Phase Ib/II TLP trial (NCT03054363) enrolled patients with HR+/HER2+ MBC treated with ≥2 HER2-targeted agents. The phase Ib primary endpoint was safety of the regimen evaluated by NCI CTCAE version 4.3. The phase II primary endpoint was efficacy by median progression-free survival (mPFS). Results: Forty-two women ages 22 to 81 years were enrolled. Patients received a median of two lines of therapy in the metastatic setting, 71.4% had visceral disease, 35.7% had CNS disease. The most common treatment-emergent adverse events (AE) of grade ≥3 were neutropenia (64.3%), leukopenia (23.8%), diarrhea (19.0%), and fatigue (14.3%). Tucatinib increased AUC 10–19 hours of palbociclib 1.7-fold, requiring palbociclib dose reduction from 125 to 75 mg daily. In 40 response-evaluable patients, mPFS was 8.4 months, with similar mPFS in non-CNS and CNS cohorts (10.0 months vs. 8.2 months; P = 0.9). Overall response rate was 44.5%, median duration of response was 13.9 months, and clinical benefit rate was 70.4%; 60% of patients were on treatment for ≥6 months, 25% for ≥1 year, and 10% for ≥2 years. In the CNS cohort, 26.6% of patients remained on study for ≥1 year. Conclusions: TLP combination was safe and tolerable. AEs were expected and manageable with supportive therapy and dose reductions. TLP showed excellent efficacy for an all-oral chemotherapy-free regimen warranting further testing. See related commentary by Huppert and Rugo, p. 4993
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (20)
Ulka Vaishampayan
Professor
University of Michigan
Srinivas Ramachandran
Assistant Professor
University of Colorado Anschutz Medical Campus
Sherene Loi
University of Melbourne
Joohyuk Sohn
Yonsei University College of Medicine
Jennifer Specht
Professor
Fred Hutchinson Cancer Research Center
Jennifer Diamond
Professor of Medicine with Tenure
University of Colorado Anschutz Medical Campus
Angelo D'Alessandro
Full Professor
University of Colorado Anschutz Medical Campus
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Carol A. Sartorius
University of Colorado Anschutz Medical Campus
Elgene Lim
Clinical Academic/Professor of Medicine
University of New South Wales
Richard Baird
Clinical Research Professor in Breast Cancer Therapeutics
University of Cambridge
Virginia F. Borges
Professor of Medicine
University of Colorado Cancer Center
Robert Wesolowski
Assistant Professor
Ohio State University
Elena Shagisultanova
assistant professor, medical oncology
University of Denver
Aditya Bardia
UCLA Health
Deborah Johnson
Professor/Dean of the Graduate School
Baylor College of Medicine
Christos Vaklavas
University of Utah
Eva M. Ciruelos-Gil
Universidad Complutense de Madrid
Jessica Finlay-Schultz
Research Assistant Professor
University of Colorado Anschutz Medical Campus
Dexiang Gao
Professor
University of Colorado Anschutz Medical Campus
Make your next move.
Prepare your application
Review drafts before you send them.